Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-12
    E.g., 2018-11-12

Articles

52052 items
12:00 AM, Sep 28, 2000  |  BC Extra | Financial News

Eos raises $27.5 million

Eos Biotechnology (South San Francisco, Calif.), a genomics, bioinformatics and drug discovery company, raised $27.5 million in a private placement. Investors included Affymetrix (AFFX); Biogen (BGEN); Medarex (MEDX); U.S. Bancorp Piper Jaffray; and Robertson Stephens....
12:00 AM, Sep 28, 2000  |  BC Extra | Financial News

Biovail board approves stock split

The board of Biovail (BVF; TSE:BVF) approved a 2-for-1 stock split effective Oct. 15 on the TSE and on Oct. 16 on the NYSE for shareholders of record on Oct. 10. Prior to the split,...
12:00 AM, Sep 28, 2000  |  BC Extra | Clinical News

Zarix begins Phase III

Zarix (Berwyn, Penn.) began an international Phase III trial of its Thymitaq nolatrexed (AG337) to treat hepatocellular carcinoma. Zarix licensed Thymitaq from Agouron Pharmaceuticals (La Jolla, Calif.), a subsidiary of Pfizer (PFE). Agouron ceased Phase...
12:00 AM, Sep 28, 2000  |  BC Extra | Clinical News

Iomed starts Phase III

IOX said it will start in October a 300-patient Phase III study of dexamethasone delivered using its Phoresor system for non-invasive, site-specific delivery, to treat acute local inflammation. The trial will enroll patients with epicondylitis....
12:00 AM, Sep 28, 2000  |  BC Extra | Company News

Biovail receives FDA approval

The FDA granted final marketing approval for BVF's generic version of Procardia XL nifedipine, which is marketed by Pfizer (PFE, New York, N.Y.) to treat hypertension and angina. Partner Teva (TEVA) will launch the product...
12:00 AM, Sep 28, 2000  |  BC Extra | Politics & Policy

VA still fails to protect research subjects

The U.S. Veterans Administration hospital network and affiliated university hospitals routinely fail to comply with regulations that are designed to safeguard human subjects who participate in medical experiments, according to a General Accounting Office investigation...
12:00 AM, Sep 28, 2000  |  BC Extra | Financial News

FibroGen raises $56.5 million

FibroGen (South San Francisco, Calif.) raised $56.5 million in a venture financing. Investors included Franklin Templeton Investments; American Express Financial Advisors; BioFund Ventures; Life Sciences Venture Fund; Hotung Ventures; IBJ Investments; ORIX; Asahi Life; and...
12:00 AM, Sep 27, 2000  |  BC Extra | Company News

Bristol-Myers and Lexicon in knockout deal

BMY and LEXG entered a five-year target validation agreement. BMY will gain access to LEXG's LexVision database of phenotypic data derived from LEXG's knockout mouse technology and LEXG's OmniBank library of embryonic stem cell clones....
12:00 AM, Sep 27, 2000  |  BC Extra | Top Story

FDA requests second trial from Endo

During a Sept. 25 meeting, the FDA requested a second pivotal chronic multiple dosing study of ENDP's MorphiDex opioid analgesic in addition to a pivotal study previously submitted to the agency. The company said the...
12:00 AM, Sep 27, 2000  |  BC Extra | Company News

Proteome subsidiary picks new CEO

Proteome (LSE:PRM) hired Gerard McGarrity as CEO of its U.S. gene therapy subsidiary Intronn (Durham, N.C.). McGarrity was the CSO of Cambridge Genetics....

Pages